Moritz Eissmann

Head of Cytokine and Cancer Signalling Group @ONJCRI

[ONJ Cancer Research Institute @ONJCRI]

🎉 Thrilled to share that an @ONJCRI and @latrobe led project has been awarded $5 million from the @nhmrc, to investigate treatment resistance in colorectal cancer. Congratulations to Prof John Mariadason, Dr Lisa Mielke and collaborators!

Read more 👉 https://t.co/9sbru45oxI

[ONJ Cancer Research Institute @ONJCRI]

💫 Our new publication in @scisignal reveals insights into gastric cancer progression! Funded by @latrobe, Dr Shoukat Sterle & team found inhibiting DCLK1 reduces tumour growth and prevents cancer from reshaping its environment.

Congrats to the team!
👉 https://t.co/L938JsYJz3

[ONJ Cancer Research Institute @ONJCRI]

🎉 NEW SPEAKERS ALERT 🎉

Join us at the ONJCRI 10th Anniversary Conference on Sept 19-20, 2024! Get insights from top experts on cancer research & more. Register & submit abstracts by Aug 25! 🔗 Register Here https://t.co/gPnOzm19CR

#CancerResearch #ONJCRI #UnitedAgainstCancer

[Moritz Eissmann @EissmannMo95094]

I thank the co-leads for this work Dr Anne Huber, Dr Amr Allam @The__Sci, Prof Matthias Ernst @lab_ernst , all co-authors and people as well as funders and institutions (@ONJCRI, @latrobe) that have made this work possible! Lets keep up the good work!

[Moritz Eissmann @EissmannMo95094]

In our new publication in @CellReports,
we established a series of compound mutant mice harbouring KRAS, PI3K and TP53 mutations and corresponding organoids to investigate the dependency on IL6/IL11/STAT3 signalling for each gastric cancer disease step. https://t.co/vzMOM2Nhrn

[Moritz Eissmann @EissmannMo95094]

While all disease stages present with high STAT3 signalling, we discovered that TP53 mutations drive an IL11 to IL6 dependency switch in the transition from early to late-stage stomach carcinoma progression.

[bioRxiv Cancer Bio @biorxiv_cancer]

Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within Interleukin-6 family cytokines https://t.co/aj7rxAdxgf #biorxiv_cancer

[ONJ Cancer Research Institute @ONJCRI]

Prof Matthias Ernst, Dr Moritz Eissmann & team receive prestigious @CancerVic Grants-In Aid funding for research into pancreatic cancer. Congratulations @lab_ernst !

To learn more about our #CancerResearch visit https://t.co/4PceholYOU #Anticancer